eyecro data to be presented at ARVO 2016 in Seattle
Similar Posts
EyeCRO scientists contribute to paper published in Biology
Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization Click here to read more
EyeCRO CEO Rafal Farjo Named ARVO Foundation Chair
We are excited to announce that our CEO, Rafal Farjo, Ph.D., has been named the ARVO Foundation for Eye Research Chair. This prestigious appointment highlights Dr. Farjo’s extensive experience and dedication to advancing ocular research over the past 25 years. As the CEO of EyeCRO, Dr. Farjo has been instrumental in helping clients develop new…
eyecro’s First Published Article in Molecular and Cellular Biology
Retinol-Binding Protein 4 Induces Inflammation in Human Endothelial Cells by a NADPH Oxidase- and Nuclear Factor Kappa B-dependent and Retinol-Independent Mechanism Krysten M. Farjoa,#, Rafal A. Farjob, Stacey Halseya, Gennadiy Moiseyeva and Jian-xing Maa aDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma beyecro LLC, Oklahoma City, Oklahoma ABSTRACT Serum retinol-binding protein…
NIH-Industry Collaboration Advances Gene-Agnostic Treatment for Retinal Disease
A new study from the National Institutes of Health (NIH) has shown promising results for reserpine—a medication originally approved in 1955 for high blood pressure—as a potential treatment to prevent vision loss caused by inherited blinding diseases such as retinitis pigmentosa. In preclinical studies, reserpine protected retinal neurons essential for vision, particularly in females. Unlike…
EyeCRO Contributes to LUXTURNA® Potency Assay Validation
We’re proud to share that EyeCRO CEO Dr. Rafal Farjo is a co-author on a new publication validating a cell-based potency assay for LUXTURNA®, the first gene therapy approved in the U.S. for an inherited retinal disease. As stated in the publication: “This represents the first report of validation studies supporting an in vitro cell-based…
eyecro co-authors paper in Molecular and Cellular Biology studying mechanisms leading to Diabetic Retinopathy
Serum retinol-binding protein (RBP4) is the sole specific transport protein for retinol in the blood, but it is also an adipokine with retinol-independent, pro-inflammatory activity associated with obesity, insulin resistance, type 2 diabetes, and cardiovascular disease. Here we show that RBP4-Tg mice develop progressive retinal degeneration, characterized by photoreceptor ribbon synapse deficiency and subsequent bipolar…
